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Copyright © 2018 The Authors. Published by Wolters Kluwer Health, 
Inc. on behalf of The American Society of Plastic Surgeons. This 
is an open-access article distributed under the terms of the Creative 
Commons Attribution-Non Commercial-No Derivatives License 4.0 
(CCBY-NC-ND), where it is permissible to download and share the 
work provided it is properly cited. The work cannot be changed in 
any way or used commercially without permission from the journal.
INTRODUCTION
The keystone perforator island flap, adapted from the 
Bezier flap,1 was described2 and popularized by Behan et 
al.3 It is a local, type A fasciocutaneous advancement flap, 
consisting of 2 V to Y advancements, with a blood supply 
based on random perforating vessels (Fig. 1).4 Since the 
introduction of the keystone flap, 4 subtypes have been 
described, mainly based on the size of the defect and the 
extent of flap dissection (Table 1).5 The keystone flap has 
been demonstrated to be a versatile form of head and 
neck,6–9 nasal,10 lower limb,11,12 periarticular,5 and post-
burn excision reconstruction.13
In our opinion, the advantages of the keystone flap 
over split-thickness skin grafts (SSG) are clear: a better 
donor-recipient color match, less contour defect (Fig. 2), 
more supple and robust soft tissue coverage, no donor-
site morbidity, lower complication rate, and simplified re-
covery. Qualitative and quantitative assessments of these 
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Background: The keystone perforator island flap provides a versatile form of re-
construction. Perceived benefits include better donor-recipient color match, less 
contour defect, and fewer complications. To date, there has been no high-quality 
evidence comparing keystone flaps to split-thickness skin grafts (SSG) from both a 
qualitative and quantitative point of view.
Methods: The Objective and Patient Reported Assessments of Skin grafts versus 
Keystone flap cohort study compares keystone flaps with SSGs for the reconstruc-
tion of skin cancer defects. Patient-reported outcome measures were collected 
using the EuroQol 5 dimension scale and Patient and Observer Scar Assessment 
Scale (POSAS) questionnaires. Objective assessments of skin quality were assessed 
with the Courage and Khazaka system. Cost analysis was also performed.
Results: Thirty-eight patients were studied: 20 keystone flaps and 18 SSGs. The key-
stone group had higher EuroQol 5 dimension scale scores (keystone median = 1.0; 
SSG median = 0.832; P = 0.641) indicating better general quality of life and lower 
POSAS scores indicating better disease/condition specific quality of life (keystone 
mean = 27.7; SSG mean = 35.7; P = 0.323). Observer POSAS scores were signifi-
cantly lower in the keystone group compared with the SSG group (keystone mean 
= 10.889; SSG mean = 17.313; P < 0.001). Preservation of sensation was significantly 
better in keystone flaps (P = 0.006). There was an average £158/$207 (15%) saving 
when performing a keystone flap.
Conclusion: This pilot study demonstrates a number of possible benefits of keystone 
flaps over SSGs. The results demonstrate the need for further research comparing 
these reconstructive options. We propose a prospective, controlled study using the 
methods developed in this pilot study. (Plast Reconstr Surg Glob Open 2018;6:e2024; 
doi: 10.1097/GOX.0000000000002024; Published online 16 November 2018.)
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 advantages are undocumented in the literature, aside 
from complication rates, with the largest study to date 
of 176 patients indicating only 4.6% of all keystone flaps 
sustained a complication requiring therapeutic interven-
tion,14 compared with a reported failure rate of SSGs in 
the lower limb as high as 66%.15
To our knowledge, there have been no studies compar-
ing the results of keystone flap reconstruction to SSGs. In 
the era of joint patient-clinician decision-making, it is of 
benefit to the plastic surgery community to have objective 
and patient-reported outcome data available to support 
decision-making processes. We present the Objective and 
Patient Reported Assessments of Skin grafts versus Keystone 
flaps (OPRASK) study, providing evidence to support clini-
cal decision-making and a study protocol for further, large-
scale assessment of these 2 reconstructive options.
STUDY OBJECTIVES
Primary Objective
 • To determine if there is a difference in POSAS and Eu-
roQol 5 dimension scale (EQ-5D-5L) scores between 
keystone flaps and SSGs for the closure of postskin can-
cer excision defects.
Secondary Objectives
 • To determine if there is objective evidence to suggest that 
there is a difference in the outcome between keystone 
flaps and SSGs for postskin cancer excision defects.
 • To examine the health economic costs associated with 
keystone flaps and SSGs.
Fig. 1. Design of a keystone fasciocutaneous advancement flap.
Table 1. Four Subtypes of the Keystone Flap Are Described 
Although Type I and IIa Are the Most Commonly Used
Keystone 
Subtype Principles and Surgical Application
Type I
Defect less than 2 cm in width
Lateral deep fascia not divided
Type IIa Defects larger than 2 cm in width
Lateral deep fascia divided
Type IIb Used in addition to a skin graft in large defect to 
reduce the tension
Type III Large defects of 5–10 cm in width where 2 keystone 
flaps either side of the defect are raised
Type IV Rotational keystone flap raised with up to 50% 
 undermining
Table modified from Behan2 and Pelissier et al.4
Fig. 2. Schematic demonstrating the difference in contour and tissue quality between a keystone flap 
and a split thickness skin graft.
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Methods
The OPRASK study is a retrospective cohort study 
comparing a group of patients who have undergone key-
stone flap reconstruction with a group who have received 
an SSG for closure of a postskin cancer resection defect. 
The study protocol was reviewed by the Joint Study Review 
Committee at Swansea University and received ethical ap-
proval from the East of England – Cambridgeshire and 
Hertfordshire Research Ethics Committee (REC number 
230581). Patient data were pseudo-anonymized using a 
unique identifier and managed in accordance with the 
Data Protection Act 1998 and the 2018 General Data Pro-
tection Regulations. The principles of the Declaration of 
Helsinki were followed at all times.
Patient Identification and Inclusion
Electronic patient records, operation logs and elec-
tronic photographs of patients under the care of the se-
nior author (I.S.W.) were used to identify patients who had 
undergone keystone flap reconstruction. A case-matched 
cohort of SSGs was identified taking into account age, sex, 
body site, and defect size. Inclusion and exclusion criteria 
are documented in Table 2.
Patient-reported Outcome Measures
Patient-reported outcome measures (PROMs) are 
completed by patients to capture one or more aspects 
of their health and wellbeing, typically taking the form 
of standardized and validated questionnaires.16 They are 
broadly divided into generic PROMs (those that assess 
general aspects of health and wellbeing) and site, disease, 
or condition-specific PROMs (which cover aspects that are 
specific to that condition or anatomical domain).17 To be 
meaningfully used, they must be psychometrically robust, 
as described elsewhere.17,18 As the main aim of this study 
was to assess the patient perspective of the difference be-
tween keystone flaps and SSGs, both generic and condi-
tion-specific PROMs were used. To assess scar burden and 
quality, the scar-specific Patient and Observer Scar Assess-
ment Scale (POSAS)19,20 was used. First presented in 2005 
by Draaijers et al.,21 it is the most commonly used scar-spe-
cific PROM. It consists of 2 scales, one completed by the 
patient and the other by an observer, each consisting of 
6 items scored on a 10-point scale.22 The patient scale as-
sesses the scar for color, pliability, thickness, itching, pain, 
and irregularity compared with their normal skin. The ob-
server rating scale consists of 6 items: vascularity, pigmen-
tation, pliability, thickness, relief, and surface area. Total 
scores range between 6 and 60, with 6 being perfectly nor-
mal skin and 60 being the worst imaginable scar. The PO-
SAS has been well validated in burns scars21,23 and linear 
scars22 making it well suited for application in this study.
The EQ-5D-5L, a simple generic measure of health 
status, is the most widely used generic PROM internation-
ally,24 is recommend by The National Institute for Health 
and Care Excellence25 and used extensively in the National 
Health Service PROM program in the United Kingdom.16 
It consists of 5 descriptive dimensions, covering mobility, 
self-care, usual activity, pain/discomfort, and anxiety/de-
pression along with a 100 mm visual analog scale (VAS) 
ranging from “best imaginable health” to “worst imagin-
able health.” The EQ-5D-5L has a 5-level response cat-
egory for each item, resulting in a 5-digit code. This is 
converted to an index value using an anchor-based scale 
in which 1 represents full health and 0 a state equivalent 
to being dead.26
Objective Assessment
In addition to collecting PROM data, objective mea-
sures of skin quality were also recorded. The Courage and 
Khazaka system (Courage and Khazaka GmbH, Cologne, 
Germany)27 was used to investigate the elasticity, pliability, 
color, moisture level, and trans-epidermal water loss of the 
skin of the reconstructions.
Elasticity and pliability were measured using the reli-
able and sensitive Cutometer MPA 580 probe,28,29 which 
contained a 6 mm aperture into which the skin was drawn 
using 450 mbar of negative pressure.30 The software 
shipped with the Cutometer calculates a number of pa-
rameters based on the deformation curves generated as 
a result of the negative pressure. The R0 and Q0 param-
eters, both of which demonstrate firmness, the R2 param-
eter, which demonstrates elasticity and the R9 parameter 
indicating the tiring effect of the skin over multiple mea-
surements, were all reported.
Trans-epidermal water loss was measured using the 
Tewameter TM30031 probe, a commonly used device in 
the literature for both normal and scarred skin.32,33 Hy-
dration of the stratum corneum was measured using the 
Corneometer CM 825 probe.34,35 Skin color was measured 
with the Mexameter MX 18 using principles of reflectance 
spectroscopy.28,36 To complete a comprehensive quanti-
tative assessment, skin sensation was assessed using the 
Semmes Weinstein monofilament test37 (Table 3).
Study Procedure
All patients meeting the inclusion criteria were invited 
to participate in the study via a comprehensive letter and 
Table 2. Predefined Inclusion and Exclusion Criteria for the 
OPRASK Study
Inclusion 
criteria Population •  18 years old or above
  •  Any sex
  •  Any ethnicity
 Intervention •  Keystone fasciocutaneous flap
  •  Senior author as lead clinician
  •  Proven or suspected skin cancer
 Comparator •  Split-thickness skin grafts matched 
to keystone group with similar 
defect size and demographics
  •  Proven or suspected skin cancer
Exclusion 
criteria
Population •  Under 18 years of age
  •  Unable to provide consent
 Intervention •  Free flap reconstruction
  •  Nonkeystone fasciocutaneous flaps
  •  Mixed reconstructive approaches, 
including those utilizing keystone 
flaps in addition to an alternative 
reconstructive modality
 Comparator •  Full-thickness skin grafts or dermal 
substitutes
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information pack, followed-up with a second letter and 
phone call as required. Patients were invited to attend one 
of 3 study days; however, if they were unable to attend they 
could complete a questionnaire pack (containing the PO-
SAS and EQ-5D-5L) and return this by post. All patients 
gave written consent and travel expenses were reimbursed 
for those attending a study clinic.
At study clinics, each patient rotated through 3 sta-
tions, completing the POSAS and EQ-5D-5L and under-
going testing with the Semmes Weinstein monofilament 
and the Courage and Khazaka equipment. Room tem-
perature, humidity, and ambient light conditions were 
consistent throughout the study. Objective investigations 
were conducted at least 10 minutes after the patient ar-
rived, allowing skin blood flow to return to normal fol-
lowing exertion. Each objective assessment was repeated 
5 times, from both the keystone flap/SSG and a corre-
sponding area of normal skin on the contralateral side. 
Average results from the abnormal side were subtracted 
from the normal side in the final analysis such that each 
patient acted as their own internal control. The observer 
section of the POSAS was completed by 2 independent 
clinicians (T.D. and A.K.), and the average score used to 
reduce the risk of bias. Clinical notes were interrogated 
for basic demographic data, details regarding lesion size 
and type, type of reconstruction, and the postoperative 
course including recurrence and complications. To calcu-
late follow-up duration, the point at which they attended a 
study clinic or completed the questionnaire pack was used 
as the most recent data and the difference between this 
and their operation date used.
Statistical Analysis
Total scores were calculated for POSAS and EQ-5D-5L 
according to the developer’s guidelines. Missing data were 
handled by 2 approaches. Any questionnaires with more 
than 50% missing data were excluded from the analysis. 
For data where repeat measures were taken (objective skin 
measurements), if greater than 60% of the repeats were 
recorded, the mean of these were calculated and used to 
replace the missing data. This method is used throughout 
the statistical literature, although others exist.38 If less than 
60% of the data were available, all data for this measure-
ment property were excluded.
Patient numbers were limited by the cohort size. A post 
hoc power calculation using the number recruited, PO-
SAS score effect size and, α = 0.05, demonstrated power of 
0.32 (G*Power V3.1).
All data were collated in Excel (Microsoft, Redmond, 
Wash.) and analyzed in SPSS V.22 (IBM Analytics, N.Y.). 
Tests for normality were performed, with normally distrib-
uted data compared using parametric analysis [data pre-
sented as mean (M) ± SD] and skewed data analyzed with 
nonparametric tests [data presented as median (Md) ± in-
terquartile range (IQR)]. Significance was taken as P < 0.05.
RESULTS
Thirty-eight patients responded to the invitation and 
agreed to be enrolled, with 17 attending a study clinic and 
21 returning the questionnaire pack only (Fig. 3). Baseline 
characteristics can be seen in Table 4. The average patient 
age and length of follow-up were significantly lower in the 
keystone compared with the SSG group (t test; P = 0.001), 
but sex was evenly distributed in both groups (chi-square; 
P = 1.000). Defect size did not significantly differ between 
groups (Mann Whitney U test; P = 0.264).  Figures 4 and 5 
demonstrate an example of a keystone flap from the co-
hort studied.
Patient-reported Data
Anchored index scores for EQ-5D-5L were calculated 
for each patient. The median score in the keystone flap 
group was 1.0 (IQR = 0.4) versus 0.8 (IQR = 0.3) in the SSG 
group. A lower score represents a worse level of health and 
thus there is a trend toward the SSG group having a lower 
overall quality of life. This difference was, however, not sig-
nificant (Mann Whitney U test, z = ˗ 0.51; P = 0.641; r = 0.08).
To investigate if age plays a role in EQ-5D-5L scores, 
a one-way analysis of covariance was performed. After ad-
justing for age, no significant difference was demonstrated 
between the EQ-5D-5L scores in either procedural group 
(F = 0.47; P = 0.498). Partial eta squared for the covariant 
was 0.077, suggesting a small effect size and that only 7.7% 
of the variance in the EQ-5D-5L score is explained by age.
No significant difference in VAS was demonstrated 
between those who underwent a keystone flap (M = 81.8; 
SD = 15.3) and those who underwent an SSG (M = 77.7; 
SD = 17.4; P = 0.455, two-tailed). There is, however, a trend 
Table 3. Summary of Patient-reported and Objective 
Measurements Used in the OPRASK Study
Assessment Description
Patient and 
Observer Scar 
Assessment Scale 
(POSAS)
-  Two scales, 1 patient completed and 1 
observer completed
 - Six items in each
 - Scored on a 10-point scale
 - Scores between 6 and 60
 -  Higher scores indicate worse scars/skin 
quality
EuroQol five 
dimension scale 
(EQ-5D-5L)
- Five items
 - Five point scale to each item
 -  VAS ranging from “best” to “worst” imagina-
ble health
 - 1 = best health, 0 = worst health
Cutometer - Measure of elasticity and pliability
 -  Uses negative pressure to deform a small area 
of skin
Tewameter - Measures TEWL
 - Based on Fick’s law of diffusion between 2 
  sensors
 -  Increased TEWL in poor quality or damaged 
skin
Corneometer - Measures hydration of the stratum corneum
Mexameter - Measure of skin color
 - Uses principles of reflectance spectroscopy
Semmes Weinstein 
monofilament
- Commonly used to test sensation
 -  Five monofilaments of varying diameters, 
which deform at different pressures
TEWL, trans-epidermal water loss.
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toward a higher VAS in the keystone group, suggesting a 
greater quality of life as seen in the index values.
Table 5 shows Patient Scar Assessment Scale (PSAS) 
results. A Bonferroni correction was applied to the alpha 
value for between-group analysis of the individual PSAS 
scores to reduce the risk of a type 1 error, giving an alpha of 
0.008 for significance. The median total PSAS score for the 
keystone flap group was 11 (IQR, 10) and 13 (IQR, 14.5) 
for the SSG group. This was nonsignificant (Mann Whitney 
U test, z = 0.493; P = 0.622; r = 0.08). Questions relating to 
scar color (PSAS 3) and scar irregularity (PSAS 6) showed 
the highest median values, indicating worse results.
A significant difference between the observer POSAS 
scores for the keystone flap group (M = 10.9; SD = 2.4) and 
the SSG group (M= 17.3; SD = 3.1; P < 0.001, independent 
samples t test) was observed (Fig. 6).
Total POSAS scores were calculated (sum total of PSAS 
and OSAS scores). These were lower in the keystone group 
(M = 27.7; SD = 16.8) than the SSG group (M = 35.7; SD = 
14.3), suggesting that keystones are more comparable to 
normal skin to both patients and clinical observers. This 
was, however, nonsignificantly different (P = 0.323; eta 
square = 0.08; independent samples t test).
Table 6 demonstrates the results of correlation test-
ing between the total PSAS score, the average total OSAS 
score, and the EQ-5D-5L. It was hypothesized that both pa-
tients and clinicians would have similar views with regard 
to the outcome of surgery and that the EQ-5D-5L would 
have a negative correlation with POSAS scores (lower 
POSAS scores and higher EQ-5D-5L scores both indicate 
‘better’ scar or general quality of life, respectively). A be-
tween-group analysis was also performed, investigating the 
relationship between PSAS and OSAS in the keystone flap 
and SSG groups. Both groups showed a large positive cor-
relation between PSAS and OSAS, although this did not 
reach the level of significance (keystone; rho = 0.52; confi-
dence interval = 0.08–0.79; P = 0.192 and SSG; rho = 0.52; 
confidence interval = 0.05–0.80; P = 0.188).
Objective Data
In assessing sensation between the nonoperated side 
and the operated side, the data were split into those people 
in each procedural group (keystone flap or SSG) that did 
or did not have a change in the categorical score on the 
Semmes Weinstein monofilament test between their normal 
and abnormal sides. This generated 4 categories (keystone 
– Yes, keystone – No, SSG – Yes, SSG – No), which were com-
pared in a two-by-two table using the Pearson chi-square test 
(Table 7). Significantly fewer people in the keystone group 
experienced a reduction in sensation compared with their 
normal side, indicating a strong association between the type 
of procedure and the reduction in sensation compared with 
the normal side (chi-square = 7.61; P = 0.006; phi = ˗0.79).
Table 8 shows the results of the Courage and Khazaka 
data. No significant difference between keystone flaps 
and SSGs were demonstrated in any of the objective pa-
rameters measured. There was, however, a trend toward 
SSGs being firmer that keystone flaps (keystone Q0 = 17.8 
versus SSG Q0 = 5.5). Furthermore, both demonstrated a 
reduction in their trans-epidermal water loss, but an in-
crease in hydration in the stratum corneum.
Complications
There were 2 complications in the keystone group 
(10%) and 7 in the SSG group (39%). There was 1 infec-
tion in the keystone group, successfully treated with oral 
antibiotics and 1 hypertrophic scar. In the SSG group, 2 
Fig. 3. Study flow diagram demonstrating recruitment to the 
OPRaSK study.
Table 4.  Baseline Characteristics of Patients Included in 
the Study
Group Keystone (n = 20) SSG (n = 18) P
Sex, n (%)    
  Male 7 (18.4) 6 (15.8)  
  Female 13 (34.2) 12 (31.6) 1.000*
Age 68.9 ± 10.20 80.9 ± 9.26 0.001†
Lesion, n (%)    
  BCC 4 (10.5) 7 (18.4)  
  SCC 3 (7.9) 9 (23.7)  
  Melanoma scar 13 (34.2) 2 (5.3) 0.003*
Location, n (%)    
  Head and neck 3 (7.9) 2 (5.3)  
  Trunk 4 (10.5) 1 (2.6)  
  Upper limb 3 (7.9) 4 (10.5)  
  Lower limb 10 (26.3) 11 (28.9) 0.554*
Defect size (mm2) 774.5  
(327.0, 1968.0)
977.0  
(835.5, 1533.0)
0.264‡
Follow-up (mo) 19.6 ± 6.40 28.1 ± 8.29 0.001†
Ordinal variables are expressed as absolute numbers and percentages (%) of over-
all number of patients in the study. Continuous variables are expressed as mean 
± SD (parametric data) or median ± interquartile range (nonparametric data).
*Chi-square.
†Independent samples t test.
‡Mann-Whitney U test.
BCC, basal cell carcinoma.
SCC, squamous cell carcinoma.
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people developed infections, with 1 graft overgranulated 
and 4 grafts partially or completely failed.
Excision Rate and Detection of Recurrence
One lesion was incompletely excised in the SSG group, 
with no incompletely excised lesions in the keystone 
group. There was 1 recurrence in the SSG group and 
none in the keystone group. A Fisher’s exact test was used 
to examine this relationship between these results and the 
type of reconstruction, with no evidence of a relationship 
(P = 0.474, respectively).
Cost Analysis of Keystone Flaps and Split-thickness Skin 
Grafts
Costs were calculated to include time in theater, type 
and amount of anesthetic, equipment used, sutures, dress-
ings, and follow-up appointments in the dressing clinic 
until the wound was healed (defined as the point where 
the wound could be managed without dressings at home 
by the patient which equated to a mean of 1.5 weeks for 
a keystone flap and 5.6 weeks for an SSG; Table 9). There 
was an average cost saving of £208/$268 (19.7%) in the 
keystone flap group versus the split-thickness skin graft 
(keystone flap = £850.94; SSG = £1059.45; P = 0.389, inde-
pendent samples t test).
DISCUSSION
The benefits of the keystone flap have been well 
documented for the reconstruction of defects in range 
of topographical areas,5–7,9,11–13 although there is little 
objective or patient-reported outcome data compar-
ing them to SSGs. This study aimed to generate pilot 
data to address this. Key outcomes are documented in 
Table 10.
There was a trend toward an inferior quality of life in 
the SSG group versus the keystone flap group, with lower 
median scores in both the EQ-5D-5L and EQ-5D-5L VAS in 
the SSG group. It is of note that only 7.7% of the variance 
in EQ-5D-5L score was ascribed to age.
It was hypothesized that the POSAS would provide a 
greater ability to differentiate between reconstruction 
type, given its focus on scarring. Again there was a trend 
toward “worse” scarring in the SSG group, reflected by a 
higher median total patient component of the POSAS. 
Scar color and irregularity showed the greatest difference 
between the operated side and the normal skin from a 
patient perspective. Although the EQ-5D-5L and POSAS 
scores all showed a trend toward worse results for the SSGs 
versus the keystone flaps, statistical significance was not 
achieved.
Fig. 4. examples of 2 keystone perforator flaps used to reconstruct large defects that would not closure 
primarily and would otherwise require an SSg. a, B, c, D – left shoulder. a, Preoperative lesion and key-
stone flap markings. B, Defect following lesion excision. c, inset of keystone flap at end of procedure. D, 
Postoperative follow-up at 2 weeks. e, F, Right upper back. e, intraoperative image showing excision of 
lesion and resulting defect. F, inset of keystone flap at end of procedure.
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For the clinical observer, our results show that statistically, 
the keystone flap is aesthetically and functionally preferable, 
with the observer component of the POSAS demonstrating 
a significantly lower score in the keystone group.
Significantly, fewer people in the keystone group ex-
perienced a reduction in sensation compared with the 
 normal side and there was a trend toward keystone flaps 
being firmer than SSGs. These findings are important as 
a lack of protective sensation and thinner, less robust soft-
tissue coverage, may result in acute injury or wound break-
down from frictional forces or direct trauma.
Cost analysis demonstrated that the average keystone 
flap costs £158 ($207) less than an SSG (a 15% saving). 
In an era of prudent healthcare, a reliance on rationing 
of healthcare resources and the growing incidence of skin 
cancer, there is a large health economic benefit to consider.
Although subjective and quantitative data suggest a 
trend toward better overall outcomes with a keystone flap 
versus SSGs, the lack of statistical significance is likely due 
to a number of factors. The low power, due to a modest co-
hort size and the need for nonparametric statistical analy-
sis, makes it difficult for the results to reach significance. It 
is also likely that our patient population, generally elderly, 
with a significant number living in a semirural setting, suf-
fering from cancer, is not overly concerned by the aesthetic 
or functional outcome of their reconstruction. This is sug-
Fig. 5. Postoperative follow-up at 4 weeks.
Table 5. Scores for the Patient-reported Component of the 
POSAS for the Keystone Flap and SSG Groups
Patient Scar 
Assessment Scale
Keystone 
(n = 19)
SSG  
(n = 17)  
PSAS 1 1.0 (0.0) 1.0 (0.0)
P = 0.851
z = ˗0.298
PSAS 2 1.0 (0.0) 1.0 (0.0) P = 0.851
z = 0.261
PSAS 3 3.0 (5.0) 3.0 (5.0) P = 0.778
z = 0.306
PSAS 4 1.0 (1.0) 1.0 (1.0) P = 1.000
z = ˗0.018
PSAS 5 1.0 (1.0) 1.0 (1.0) P = 0.415
z = 0.904
PSAS 6 3.0 (3.0) 3.0 (3.0) P = 0.876
z = 0.164
PSAS Total 11.0 (10.0 13.0 (14.5) P = 0.493
z = 0.622
Results presented as median (interquartile range). All differences assessed 
using Mann Whitney U for nonparametric data. Level of significance α < 0.05 
for the PSAS Total, with Bonferroni correction used for the individual PSAS 
questions, reducing α to 0.008.
Fig. 6. Mean score for the observer component of the POSaS ques-
tionnaire in the keystone flap and SSg groups. the mean score is the 
average score for each group taken from the average of 2 indepen-
dent researchers scoring each patient. SD is demonstrated. inde-
pendent samples t test was used to compare means with P < 0.001.
Table 6. Correlation between the Total PSAS, Average Total 
OSAS, and EQ-5D-5L Scores
PROM 1 2 3
1. EQ-5D-5L —   
2. PSAS -0.71* —  
3. OSAS -0.24 0.56† —
Spearman rho correlation coefficient.
*P < 0.001 (2-tailed), †P < 0.05 (2-tailed).
Table 7. Comparison of Changes in Sensation on the 
Semmes Weinstein Monofilament Test between the Normal 
and Abnormal Sides in Those Undergoing Keystone Flap or 
Split-thickness Skin Graft Reconstruction
Reconstruction 
Group
Reduction  
in Sensation
No reduction 
in Sensation  
Keystone flap 2 7  
SSG 8 0  
   n = 17
χ2 = 7.610, P = 0.006
phi = ˗0.789
PRS Global Open • 2018
8
gested by the majority of patients scoring the lowest category 
possible (1 out of 10) for a large number of the PSAS ques-
tions. It is likely that this age group is less concerned with 
the factors asked in the POSAS questionnaire than younger 
patients might be. It is our belief that in a younger popu-
lation, living in major cities, with higher expectations, that 
these results would be different. We also note a significant 
difference in the average age between both groups. This is 
likely to represent unconscious bias on the part of the clini-
cal team when recommending different treatment options 
and is something to address in a future, prospective study.
Despite being a small cohort it is important to note 
that no keystone flaps failed, whereas 4 SSGs experienced 
either partial or complete loss. This lower complication 
rate is an important finding and one that should be dis-
cussed with patients.
Trends identified suggest that a fully powered, pro-
spectively collected data set is warranted. Both EQ-5D-5L 
and POSAS questionnaires functioned well and were easy 
to administer. Similarly, sensation was easy to measure 
and provided useful information. We, however, feel that 
the collection of objective data using the Courage and 
Khazaka adds considerably to the cost and complexity of 
the study without significant benefits and as such would 
suggest this is not included in future protocols.
CONCLUSIONS
The limited cohort size available in this retrospective 
study limited its statistically power and the conclusions that 
can be drawn. However, a trend toward greater patient sat-
isfaction, better appearance, and cost savings to the health 
provider of keystone flaps over SSGs was seen. The develop-
ment of a larger, prospectively designed trial is now required 
to fully evaluate the difference and provide evidence-based 
treatment that is preferential to our patient population.
Thomas D. Dobbs, BM BCh, MA Oxon, MRCS
The Welsh Centre for Burns and Plastic Surgery
Morriston Hospital
Swansea
SA6 6NL
E-mail: tomdobbs@doctors.org.uk
Table 8. Data from the Cutometer, Mexameter, Corneometer, and Tewameter Compared between the Keystone Flap Group 
and SSG
Courage and Khazaka Probe Measurement Parameter Keystone Flap (n = 9) SSG (n = 7)  
Cutometer
R0 0.09 (0.03) 0.001 (0.20)
P = 0.247*
eta = 0.094
R2 -0.01 (0.03) -0.17 (0.23) P = 0.116*
eta = 0.193
R9 -0.01 (0.02) -0.01 (0.05) P = 0.845*
eta = 0.029
Q0 17.76 (14.68) 5.46 (43.06) P = 0.492*
eta = 0.036
Mexameter Melanin content -28.4 (51.7) 23.3 (140.4) z = 1.217†
P = 0.252
r = 0.304
Erythema content 3.0 (113.3) -13.8 (279.8) P = 0.871*
eta = 0.002
Corneometer Hydration -8.23 (8.61) -3.22 (6.16) P = 0.224*
eta = 0.143
Tewameter (measured in g/h/cm2) Trans-epidermal water loss 3.67 (8.88) 1.93 (6.67) P = 0.673*
eta = 0.013
*Parametric data analyzed using an independent samples t test, with results presented as mean and SD.
†Nonparametric data analyzed using a Mann Whitney U test, with results presented as median and interquartile range.
Table 9. Costs Used to Calculate the Average Cost of Providing a Keystone Flap or Split-thickness Skin Graft from the Point 
of Procedure to a Healed Wound
Reconstructive Group 
(Average Cost Across All 
Patients in Group)
Theater Equipment (£)  
(Plastic Surgery Set/ 
Dermatome/Skin Graft Set)
Dressings 
(£)
Sutures 
(£)
Theater  
Costs (£)
Dressing Clinic 
Costs (£) Total (£)
Keystone 230.00 2.94 8.09 530.18 79.97 850.94
SSG 437.50 4.14 10.03 310.91 297.65 1,059.45
Theater equipment: (plastic surgery set - £200, dermatome - £50, skin graft set - £50). Dressings: (chloramphenicol - £1.92, Mepitel - £0.49, Cutiplast Steril - £0.25, 
Aligisite - £1.95, Lyofoam - £1.10, Jelonet - £0.42, K-Lite crepe - £1.02). Sutures: (Mersilk - £2.78, Monocryl - £5.92, Vicryl rapide - £7.25, Ethilon - £2.17). Theater 
costs: (general anesthetic theater time - £17.90/min, local anesthetic theater time - £4.20/min). Dressing clinic: (15 minute appointment - £53.31).
Table 10. Key Study Outcomes
1
Statistically significant worse scarring in the SSG group (clini-
cian assessed)
2 Statistically significant better sensation in the keystone group
3 Keystone flaps cost the health provider 15% less the SSGs on 
average
4 Trend toward worse health-related quality of life in the SSG 
group
5 Trend toward worse cosmetic results in the SSG group (patient 
assessed)
6 Trend toward worse scarring in the SSG group
7 Trend toward reduced pliability and increased firmness in the 
SSG group
 Dobbs et al. • The OPRASK Study
9
ACKNOWLEDGMENTS
The authors would like to acknowledge the support of Enviro-
derm, (the UK supplier of Courage and Khazaka equipment) and 
Steve Atherton for Figure 1.
REFERENCES
 1. Behan FC, Terrill PJ, Breidahl A, et al. Island flaps including the 
Bezier type in the treatment of malignant melanoma. Aust N Z J 
Surg. 1995;65:870–880.
 2. Behan FC. The keystone design perforator island flap in recon-
structive surgery. ANZ J Surg. 2003;73:112–120.
 3. Behan F, Findlay M, Cheng L. The Keystone Perforator Island Flap 
Concept. Elsevier Australia; 2012.
 4. Pelissier P, Santoul M, Pinsolle V, et al. The keystone design per-
forator island flap. Part I: anatomic study. J Plast Reconstr Aesthet 
Surg. 2007;60:883–887.
 5. Jovic TH, Jessop ZM, Slade R, et al. The use of keystone flaps in 
periarticular wound closure: a case series. Front Surg. 2017;4:68.
 6. Sun Y. Keystone flap for large posterior neck defect. Indian J Surg. 
2016;78:321–322.
 7. Behan FC, Lo CH, Sizeland A, et al. Keystone island flap recon-
struction of parotid defects. Plast Reconstr Surg. 2012;130:36e–41e.
 8. Behan FC, Rozen WM, Wilson J, et al. The cervico-submental 
keystone island flap for locoregional head and neck reconstruc-
tion. J Plast Reconstr Aesthet Surg. 2013;66:23–28.
 9. Loh IW, Rozen WM, Behan FC, et al. Eyelid reconstruction: ex-
panding the applications of the keystone perforator island flap 
concept. ANZ J Surg. 2012;82:763–764.
 10. Kostopoulos E, Casoli V, Agiannidis C, et al. The keystone per-
forator island flap in nasal reconstruction: an alternative recon-
structive option for soft tissue defects up to 2 cm. J Craniofac Surg. 
2015;26:1374–1377.
 11. Martinez JC, Cook JL, Otley C. The keystone fasciocutaneous 
flap in the reconstruction of lower extremity wounds. Dermatol 
Surg. 2012;38:484–489.
 12. Huang J, Yu N, Long X, et al. A systematic review of the keystone 
design perforator island flap in lower extremity defects. Medicine 
(Baltimore). 2017;96:e6842.
 13. Al-Busaidi AA, Semalesan N, Al-Busaidi SS. Keystone design slid-
ing skin flap for the management of small full thickness burns. 
Sultan Qaboos Univ Med J. 2011;11:412–414.
 14. Moncrieff MD, Bowen F, Thompson JF, et al. Keystone flap re-
construction of primary melanoma excision defects of the leg-
the end of the skin graft? Ann Surg Oncol. 2008;15:2867–2873.
 15. Stankiewicz M, Coyer F, Webster J, et al. Incidence and predictors 
of lower limb split-skin graft failure and primary closure dehis-
cence in day-case surgical patients. Dermatol Surg. 2015;41:775–783.
 16. Devlin NJ, Appleby J. Getting the most out of PROMS. Putting 
Health Outcomes at the Heart of NHS Decision-making. The King’s 
Fund. London: 2010.
 17. Wormald JCR, Rodrigues JN. Outcome measurement in plastic 
surgery. J Plast Reconstr Aesthet Surg. 2018;71:283–289.
 18. Dobbs TD, Hughes S, Mowbray N, et al. How to decide which 
patient-reported outcome measure to use? A practical guide for 
plastic surgeons. J Plast Reconstr Aesthet Surg. 2018;71:957–966.
 19. Vercelli S, Ferriero G, Sartorio F, et al. How to assess postsur-
gical scars: a review of outcome measures. Disabil Rehabil. 
2009;31:2055–2063.
 20. Seong Hwan Bae YCB. Analysis of frequency of use of different 
scar assessment scales based on the scar condition and treatment 
method. Arch Plast Surg. 2014;41:111–115.
 21. Draaijers LJ, Tempelman FR, Botman YA, et al. The patient and 
observer scar assessment scale: a reliable and feasible tool for 
scar evaluation. Plast Reconstr Surg. 2004;113:1960–1965; discus-
sion 1966.
 22. van de Kar AL, Corion LUM, Smeulders MJC, et al. Reliable and 
feasible evaluation of linear scars by the Patient and Observer 
Scar Assessment Scale. Plast Reconstr Surg. 2005;116:514–522.
 23. van der Wal MB, Tuinebreijer WE, Bloemen MC, et al. Rasch 
analysis of the Patient and Observer Scar Assessment Scale 
(POSAS) in burn scars. Qual Life Res. 2012;21:13–23.
 24. Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, 
present and future. Appl Health Econ Health Policy. 2017;15: 
127–137.
 25. National Institute for Health and Care Excellence. Guide to the 
Methods of Technology Appraisal 2013. London, United Kingdom: 
National Institute for Health and Care Excellence (NICE); 
2013.
 26. Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related qual-
ity of life: an EQ-5D-5L value set for England. Health Econ. 
2018;27:7–22.
 27. Hua W, Xie H, Chen T, et al. Comparison of two series of non-
invasive instruments used for the skin physiological proper-
ties measurements: the ‘Soft Plus’ from Callegari S.p.A vs. the 
series of detectors from Courage & Khazaka. Skin Res Technol. 
2014;20:74–80.
 28. Nedelec B, Correa JA, Rachelska G, et al. Quantitative measure-
ment of hypertrophic scar: intrarater reliability, sensitivity, and 
specificity. J Burn Care Res. 2008;29:489–500.
 29. Draaijers LJ, Botman YA, Tempelman FR, et al. Skin elasticity 
meter or subjective evaluation in scars: a reliability assessment. 
Burns. 2004;30:109–114.
 30. Courage and Khazaka electronic GmbH, Cologne, Germany. 
Information and operating instructions for the CutometeR 
MPA 580 and the Software CutometeR Mpa Q. 2010. Available at 
http://www.courage-khazaka.de/index.php/en/. Accessed July 
5, 2018.
 31. Rosado C, Pinto P, Rodrigues LM. Comparative assessment of 
the performance of two generations of Tewameter: TM210 and 
TM300. Int J Cosmet Sci. 2005;27:237–241.
 32. Mercurio DG, Segura JH, Demets MB, et al. Clinical scoring and 
instrumental analysis to evaluate skin types. Clin Exp Dermatol. 
2013;38:302–308; quiz 308.
 33. Lee KC, Dretzke J, Grover L, et al. A systematic review of objec-
tive burn scar measurements. Burns Trauma. 2016;4:14.
 34. Clarys P, Clijsen R, Taeymans J, et al. Hydration measurements 
of the stratum corneum: comparison between the capacitance 
method (digital version of the Corneometer CM 825®) and 
the impedance method (Skicon-200EX®). Skin Res Technol. 
2012;18:316–323.
 35. Anthonissen M, Daly D, Peeters R, et al. Reliability of repeated 
measurements on post-burn scars with Corneometer CM 825(®). 
Skin Res Technol. 2015;21:302–312.
 36. van der Wal M, Bloemen M, Verhaegen P, et al. Objective color 
measurements: clinimetric performance of three devices on nor-
mal skin and scar tissue. J Burn Care Res. 2013;34:e187–e194.
 37. McGill M, Molyneaux L, Yue DK. Use of the Semmes-Weinstein 
5.07/10 gram monofilament: the long and the short of it. Diabet 
Med. 1998;15:615–617.
 38. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for 
missing data in epidemiological and clinical research: potential 
and pitfalls. BMJ. 2009;338:b2393.
